Innovative Medicines Canada is pleased to announce the appointment of Pamela Fralick as its new President, effective immediately.
Ms. Fralick comes to Innovative Medicines Canada as a proven healthcare leader, with a wealth of experience advancing critical healthcare initiatives and a deep understanding of public policy and organizational management.
“We are extremely pleased to have Ms. Fralick lead our association at such an important time both for the country’s innovative pharmaceutical industry and in the evolution of the Canadian healthcare system,” said Michael Tremblay, Chair of the Board of Directors, Innovative Medicines Canada and President of Astellas Pharma Canada, Inc. “Ms. Fralick has had a unique opportunity to participate in many aspects of Canada’s healthcare system, and throughout her career has demonstrated a commitment to improving the lives and health outcomes of Canadians. We believe she is the right person to lead Innovative Medicines Canada as we work with our partners to build a more healthcare sustainable system.”
As the former President and CEO of the Canadian Cancer Society, Ms. Fralick led a three-year process of intense transformation, resulting in significant improvements to the operational and governance structures of the organization. Prior to this, she spent five years as president and CEO of the Canadian Healthcare Association, a federation of provincial and territorial hospital and health organizations, as well as six years as CEO of the Canadian Physiotherapy Association. She was chair of the Health Action Lobby (HEAL) and co-chair of the Canadian Coalition for Public Health in the 21st Century (CCPH21). She has also held senior positions with the Canadian Centre on Substance Abuse and Health Canada’s Alcohol and Other Drugs Unit.
“As a healthcare professional dedicated to helping Canadians live longer and healthier lives, I am honoured to represent a national association whose members are responsible for developing innovative medicines and vaccines that materially improve the quality of life for so many Canadians,” said Pamela Fralick, President, Innovative Medicines Canada. “I look forward to collaborating with all of our partners across the country to improve access to these lifesaving medicines.”
Ms. Fralick has also been a senior volunteer with the Centre for Addiction and Mental Health, the University of Ottawa Institute of Mental Health Research, Triathlon Canada and the International Triathlon Union. She is currently on the boards of Outward Bound Canada (Chair) and the Canada Dance Festival (Past Chair).
Ms. Fralick takes over from Elaine Campbell, who has been Interim President of Innovative Medicines Canada since June.
-30-
For further information:
Sarah Dion-Marquis
Media Relations
Telephone: 613-769-6510
E-mail: sdmarquis@imc-mnc.ca
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
